Search

Background:  Hepatitis C virus (HCV) genotype (GT) 1 is the most common HCV GT in Western and Central Europe. The main focus of this present work is to analyze the change of baseline characteristics of 17 093 HCV-patients with genotype 1a/1b with antiviral therapy in Germany between 2004 and 2018. We analyzed five periods: (i) 2004-2007, (ii) 2008-2010, (iii) 2010-2013, (iv) 2014-2016, (v) 2017-2018., Methods:  The present analysis is based on five German non-interventional registry studies and comprises data on 17 093 HCV-GT1 patients documented between 2004 and 2018 [ML17071, ML19464, ML21645, ML25724 (Peginterferon alfa-2a ® non-interventional study [PAN]) and the German Hepatitis C-Registry (DHC-R)., Findings:  Overall, 7662 patients were infected with HCV GT1a and 9431 patients with HCV GT1b. GT1a patients were younger (46.5 years vs. 51.2 years) and more often male (70 % vs. 52 %). Previous or ongoing drug abuse was documented more frequently for GT1a patients throughout the study periods with highest frequencies in the most recent period (2017-2018; 44 % for GT1a and 10.3 % for GT1b). Metabolic comorbidities, such as those who are overweight and those with diabetes mellitus, were associated with HCV GT1b-infected women. The GT1a ratio increased from 33.6 % (2004-2007) to 50 % (2017-2018). A relevant change in the GT1a/1b ratio was observed over time in men (2004-2007: 38 %/63 %; 2017-2018: 59 %/41 %). In contrast, only 30 % of women had GT1a infection throughout all study periods without relevant changes. There were no regional differences within Germany in HCV GT1a/1b distribution despite a higher proportion of GT1b-infected women in East Germany in 2004-2007 (86 %)., Conclusion:  A marked increase of GT1a infection associated with drug use was observed in men, but not women, in Germany between 2004 and 2018. The present data show a fundamental change in HCV epidemiology, which has an impact on therapy management and general care of hepatitis C patients in Germany., Competing Interests: Karl-Georg Simon hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie GmbH & Co.KG, Falk Pharma, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH.Yvonne Serfert hat keine Interessenkonflikte.Peter Buggisch hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie, Gilead, MSD.Stefan Mauss hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie, Gilead, MSD.Klaus H. W. Boeker hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie, Gilead.Hartwig Klinker hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie, BMS, Gilead, Janssen, MSDTobias Müller hat keine Interessenkonflikte.Uta Merle hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: CSL-Behring, FALK.Dietrich Hüppe hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie GmbH & Co. KG, Falk Pharma, Ferring Arzneimittel GmbH.Michael P. Manns hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: AbbVie, BMS, Gilead, Merck (MSD)Heiner Wedemeyer hat in den letzten 3 Jahren Zuwendungen (z. B. Vortragshonorare, Forschungsgelder oder Beraterhonorare) erhalten von: Abbott, AbbVie, Altimmune, Biotest, BMS, BTG, Dicerna, Gilead, Janssen, Merck/MSD, MYR GmbH, Novartis, Roche, Siemens, Transgene., (Thieme. All rights reserved.)